• Users Online: 361
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
Year : 2020  |  Volume : 22  |  Issue : 3  |  Page : 27-31

Role of ivermectin in COVID-19: Wishful thinking or scientific optimism

Department of Pharmacology, AFMC, Pune, Maharashtra, India

Correspondence Address:
Col (Dr) Prafull Mohan
Department of Pharmacology, AFMC, Pune - 411 040, Maharashtra
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/jmms.jmms_146_20

Rights and Permissions

Ivermectin is routinely used for indications such as strongyloidiasis, onchocerciasis, and scabies. It is also known to possess antimicrobial, anticancer, antimitotic, anti-allergic, and antiviral properties. It has been found to inhibit SARS-COV-2 in an in-vitro study, following which, a lot of interest has been generated regarding its role in the treatment of COVID-19. However, as per extrapolation from in vitro study, the current approved dose of ivermectin may not result in sufficient concentration in the lungs to have an anti-COVID-19 effect. However, a large number of trials using different ivermectin doses are underway to generate conclusive data. If ivermectin fails to show clinical benefit in ongoing trials, additional studies to address its safety at much higher doses, additional mechanisms of its action, and different routes of administration/formulations may be required. As of now, ivermectin shows promise against SARS-CoV-2, but the dose and context of its use remains nebulous.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded280    
    Comments [Add]    

Recommend this journal